We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Roche Holding, Philip Morris, HSBC, AMD, and Lockheed Martin
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 6, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Philip Morris International Inc. (PM - Free Report) , HSBC Holdings plc (HSBC - Free Report) , Advanced Micro Devices, Inc. (AMD - Free Report) and Lockheed Martin Corp. (LMT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Roche, Phillip Morris and HSBC
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG, Philip Morris International Inc., and HSBC Holdings plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Roche shares have declined -4.2% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +23.6%, reflecting reduced demand for its COVID-19 medicines and diagnostics. The decline in sales of legacy drugs like Herceptin, Avastin and MabThera has also affected revenues and will drag the top-line further. Biosimilar competition for key drugs weighs on its performance. Competition is stiff for Tecentriq as well.
However, first quarter was good on the back of the diagnostics division, which maintained its stellar performance on demand for COVID-19 tests. Nevertheless, the pharmaceuticals business also remained stable and newer drugs continue to offset the decline in sales of legacy drugs, and also approval of new drugs should also boost the top line.
Philip Morris shares have gained +14.3% over the past year against the Zacks Tobacco industry's gain of +16.5%. The Zacks analyst believes that the company has been benefiting from its pricing power, which aided its first-quarter 2022 results. The top and the bottom lines increased year on year. Strength in IQOS and the combustible business drove performance despite headwinds. Pricing for combustible products rose more than 3% and by roughly 6% excluding Indonesia. Strength in the reduced-risk products category has been benefiting the company for a while now.
However, the company has been facing supply-chain and regulatory hurdles in its Russian business, and has taken steps to scale down its operations in the region, due to the Ukraine war. The war has further disrupted the global supply chain and has increased the inflationary pressure in certain materials and services.
HSBC shares have outperformed the Zacks Banks - Foreign industry over the past year (+9.4 % vs. -5.2%). The Zacks analyst believes that a strong capital position, initiatives to strengthen digital capabilities, an extensive network and improvement in operating efficiency through business restructuring will likely keep aiding growth.
Exiting from the U.S. and French retail banking operations are expected to help the company focus on Asia. In sync with this, the acquisition of AXA Singapore insurance assets will expand the company's business in the region.
Though initiatives to improve market share in the U.K. and China will continue to support financials, these might lead to a rise in expenses, which will likely hurt HSBC's bottom line to an extent in the near term. Relatively lower interest rates across the globe (despite rate hike expectations) will likely continue to hamper revenues.
Other noteworthy reports we are featuring today include Advanced Micro Devices, Inc. and Lockheed Martin Corp..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Roche Holding, Philip Morris, HSBC, AMD, and Lockheed Martin
For Immediate Release
Chicago, IL – June 6, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Philip Morris International Inc. (PM - Free Report) , HSBC Holdings plc (HSBC - Free Report) , Advanced Micro Devices, Inc. (AMD - Free Report) and Lockheed Martin Corp. (LMT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Roche, Phillip Morris and HSBC
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG, Philip Morris International Inc., and HSBC Holdings plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Roche shares have declined -4.2% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +23.6%, reflecting reduced demand for its COVID-19 medicines and diagnostics. The decline in sales of legacy drugs like Herceptin, Avastin and MabThera has also affected revenues and will drag the top-line further. Biosimilar competition for key drugs weighs on its performance. Competition is stiff for Tecentriq as well.
However, first quarter was good on the back of the diagnostics division, which maintained its stellar performance on demand for COVID-19 tests. Nevertheless, the pharmaceuticals business also remained stable and newer drugs continue to offset the decline in sales of legacy drugs, and also approval of new drugs should also boost the top line.
(You can read the full research report on Roche here >>>)
Philip Morris shares have gained +14.3% over the past year against the Zacks Tobacco industry's gain of +16.5%. The Zacks analyst believes that the company has been benefiting from its pricing power, which aided its first-quarter 2022 results. The top and the bottom lines increased year on year. Strength in IQOS and the combustible business drove performance despite headwinds. Pricing for combustible products rose more than 3% and by roughly 6% excluding Indonesia. Strength in the reduced-risk products category has been benefiting the company for a while now.
However, the company has been facing supply-chain and regulatory hurdles in its Russian business, and has taken steps to scale down its operations in the region, due to the Ukraine war. The war has further disrupted the global supply chain and has increased the inflationary pressure in certain materials and services.
(You can read the full research report on Phillip Morris here >>>)
HSBC shares have outperformed the Zacks Banks - Foreign industry over the past year (+9.4 % vs. -5.2%). The Zacks analyst believes that a strong capital position, initiatives to strengthen digital capabilities, an extensive network and improvement in operating efficiency through business restructuring will likely keep aiding growth.
Exiting from the U.S. and French retail banking operations are expected to help the company focus on Asia. In sync with this, the acquisition of AXA Singapore insurance assets will expand the company's business in the region.
Though initiatives to improve market share in the U.K. and China will continue to support financials, these might lead to a rise in expenses, which will likely hurt HSBC's bottom line to an extent in the near term. Relatively lower interest rates across the globe (despite rate hike expectations) will likely continue to hamper revenues.
(You can read the full research report on HSBC here >>>)
Other noteworthy reports we are featuring today include Advanced Micro Devices, Inc. and Lockheed Martin Corp..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.